Macleods Pharmaceuticals IPO Analysis @ Chanakyanipothi.com , India`s Oldest & most Trusted Investment Blog.Operational since 8th December 1999, We are the Only Investment Platform in India, which has successfully completed 22 Years

Macleods Pharmaceuticals IPO Grey Market News Today #
On
Grey Market Premium Rs. –
Application Rates :Rs. –
Subject to Rates : Rs. –

Macleods Pharmaceuticals IPO Company Details
Established in 1989, Macleods Pharmaceuticals is 7th largest in the IPM , based on Domestic Sales and 2nd largest in the Covered Market in Fiscal 2021 . The company is engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas . Its domestic business comprises of branded generics, and revenue from operations in India represented 51.73% of its total revenue from operations in Fiscal 2021, which was the 3rd highest proportion of
domestic business among nine other key pharmaceutical companies . It has the highest number of WHO pre-qualified products globally with 65 registrations, and the highest number of WHO pre-qualified anti-TB product registrations with 32 registrations, as at December 31, 2021 .

Its Domestic Sales grew faster than the IPM at a CAGR of 15.3% from Fiscal 2011 to Fiscal 2021, compared to 10.8% growth in Domestic Sales of the IPM in the same period .Its chronic segment
grew at a CAGR of 12.9% from Fiscal 2017 to Fiscal 2021, the second highest growth rate among its Peers, . As a result, Domestic Sales from its chronic therapies as a proportion of its total Domestic Sales increased from 29.0% in Fiscal 2017 to 35.6% in Fiscal 2021, and further to 36.5% in the six months ended September 30, 2021. In particular, from Fiscal 2017 to Fiscal 2021, its Domestic
Sales  grew at a CAGR of 28.5%, 13.4%, 11.7%, 11.0%, and 10.4%, respectively, higher than the IPM growth of 12.3%, 11.1%, 10.8%, 6.2% and 6.9%, for the same therapies in the same periods, respectively

Macleods Pharmaceuticals was ranked amongst the top 10 companies in 8 out of top 10 therapies in the Covered Market in Fiscal 2021 .It had a portfolio of 595 brands in the IPM from Fiscal 2017 to Fiscal 2021 . Based on Domestic Sales in Fiscal 2021, it had 2 brands in the top 100 Indian brands, and 7 brands in the top 300 Indian brands.
For more information, click www.macleodspharma.com

The Promoters of Macleods Pharmaceuticals IPO
Girdharilal Bawri ,Banwarilal Bawri and  Dr. Rajendra Agarwal

Macleods Pharmaceuticals IPO Main Object
The Offer comprises tonly an Offer for Sale by the Selling Shareholders.

Macleods Pharmaceuticals IPO Details
IPO opens on (?) , 2022
IPO closes on (?) ,2022
Issue Type: Book Built Issue IPO
Issue : up to 60,482,040 Shares /Rs (?) Crore
* Fresh Issue of (?) Sh/ (?) Cr
* Offer for Sale Up to 60,482,040 Sh/ Rs. ?Cr

Face Value per share : Rs. 1
Price Band Per Equity Share: Rs. (?)
Retail Lot Size (?) Shares
Macleods Pharmaceuticals IPO Listing will at BSE,NSE

Shares offered to
QIB (?%) (?) Shares = Rs (?) Cr
NII (?%) Shares = Rs (?) Crs
RII (?%) Shares = Rs (?) Crs
Lot size: (?) Shares = (?) Forms
Min Retail Application : (?) Sh , Rs. (?)
Max Retail Application : (?) Sh, Rs (?)

Macleods Pharmaceuticals IPO Tentative timeTable
Macleods Pharmaceuticals IPO Allotment on ? 2022
Unblocking of ASBA ? 2022
Credit to Demat Accounts ? 2022
Listing on ? 2022

Macleods Pharmaceuticals IPO Financial & Analytical Ratios
Earnings per Share 2019-20 Rs 26.18
Earnings per Share 2020-21,Rs 33.74
Earnings per Share 2021-22 6M Rs 10.56
Return on Net Worth: 19-20 20.78 %
Return on Net Worth: 20-21: 53.31 %
Return on Net Worth: 20-21 6M : 14.46 %
Equity Shares prior to & after the IPO : 598,820,400 Shares
Book Value of the Share as on 31.3.2021 Rs 63.37
Book Value of the Share as on 30.9.2021 Rs 73.70
NAV per Equity Share after the Offer ?

Ratio Analysis
Upper Price Band/last EPS:
Upper offer price/Book Value Ratio
Upper offer price/BV after IPO Ratio:

Macleods Pharmaceuticals IPO Peer Comparison:
Torrent Pharmaceuticals @ PE Mulitple of 35.11
Alkem Laboratories @ PE Mulitple of 26.41
Cipla Limited @ PE Mulitple of 32.73
Sun Pharmaceutical @ PE Mulitple of 73.91
Dr. Reddy’s Laboratories @ PE Mulitple of 37.25
Lupin Limited @ PE Mulitple of 30.18
Cadila Healthcare @ PE Mulitple of 19.26
Eris Lifesciences @ PE Mulitple of 26.76
Ipca Laboratories @ PE Mulitple of 11.14

Macleods Pharmaceuticals IPO Lead Managers
Kotak Mahindra Capital Company, Citigroup Global Markets,Edelweiss Financial Services, ICICI Securities,Nomura Financial Advisory
Registrar to Macleods Pharmaceuticals IPO
Kfin Technologies India pvt ltd.

Registered Office of Macleods Pharmaceuticals
304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai, 400059
Company Secretary & Compliance Officer : Siddhesh Mahadeo Rane

#This is only coverage of News related to Grey Market . We donot deal in Grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.